C₂N Diagnostics

C₂N Diagnostics is a specialized diagnostics company with the vision of delivering clarity through innovation®. C₂N is committed to providing exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C₂N’s biomarker services and products, based on high-resolution mass spectrometry, can be used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials to test novel therapies for neurodegeneration; and providing innovative tools to help healthcare researchers better understand new disease mechanisms, identify new therapeutic targets, and conduct vital epidemiological studies to improve global public health. C₂N assays have been utilized in over 150 Alzheimer's disease and other studies across the United States and globally. These include landmark treatment and prevention trials involving disease-modifying therapies (DMTs) aimed at altering the trajectory of Alzheimer’s progression. C₂N collaborates with multinational pharmaceutical and biotechnology companies, leading academic institutions, the National Institute on Aging, the Alzheimer's Association, and other nonprofit organizations and consortia. Peer-reviewed publications have reported over 15,000 Precivity™-related biomarker measurements, with additional manuscripts currently under review.